This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Hisamitsu Pharmaceutical 향후 성장

Future 기준 점검 0/6

Hisamitsu Pharmaceutical 의 수익은 연간 1.7% 감소할 것으로 예상되는 반면, 연간 수익은 4% 로 증가할 것으로 예상됩니다. EPS는 연간 0.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 4.9% 로 예상됩니다.

핵심 정보

-1.7%

이익 성장률

0.21%

EPS 성장률

Pharmaceuticals 이익 성장	12.9%
매출 성장률	4.0%
향후 자기자본이익률	4.90%
애널리스트 커버리지	Low
마지막 업데이트	25 Apr 2026

최근 향후 성장 업데이트

Recent updates

분석 기사 • Jan 06

What Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) 25% Share Price Gain Is Not Telling You

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) shareholders have had their patience rewarded with a 25% share price...

분석 기사 • Jan 05

These 4 Measures Indicate That Hisamitsu Pharmaceutical (TSE:4530) Is Using Debt Safely

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

분석 기사 • Dec 18

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its periodic dividend on the...

분석 기사 • Jul 11

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) periodic dividend will be increasing on the 7th of November to...

분석 기사 • Jun 27

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) will increase its dividend on the 7th of November to ¥60.00, which is...

분석 기사 • Apr 18

We Think That There Are Issues Underlying Hisamitsu Pharmaceutical's (TSE:4530) Earnings

Unsurprisingly, Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) stock price was strong on the back of its healthy...

분석 기사 • Mar 07

With EPS Growth And More, Hisamitsu Pharmaceutical (TSE:4530) Makes An Interesting Case

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

분석 기사 • Feb 17

Does Hisamitsu Pharmaceutical (TSE:4530) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

분석 기사 • Jan 13

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

분석 기사 • Dec 30

Hisamitsu Pharmaceutical (TSE:4530) Is Due To Pay A Dividend Of ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

분석 기사 • Nov 27

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) will pay a dividend of ¥45.00 on the 26th of May. Based on this...

분석 기사 • Nov 08

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

분석 기사 • Nov 04

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

분석 기사 • Oct 17

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) healthy profit numbers didn't contain any surprises for investors. We...

분석 기사 • Sep 16

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...

분석 기사 • Aug 20

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) dividend will be increasing from last year's payment of the same...

분석 기사 • Jul 26

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be paying its dividend of...

분석 기사 • Jul 11

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

분석 기사 • Jun 27

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

분석 기사 • Jun 13

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

분석 기사 • Apr 09

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

With a price-to-earnings (or "P/E") ratio of 20.9x Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) may be sending...

분석 기사 • Mar 18

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

이익 및 매출 성장 예측

TSE:4530 - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
2/28/2029	176,797	13,067	N/A	16,324	1
2/29/2028	167,285	12,014	4,281	14,904	1
2/28/2027	159,685	11,973	5,665	16,289	1
2/28/2026	163,024	19,160	9,428	17,478	N/A
11/30/2025	159,267	19,988	N/A	N/A	N/A
8/31/2025	155,493	19,682	8,355	16,556	N/A
5/31/2025	154,861	19,534	N/A	N/A	N/A
2/28/2025	156,006	21,758	4,991	18,765	N/A
11/30/2024	150,132	15,537	N/A	N/A	N/A
8/31/2024	150,185	14,650	176	18,593	N/A
5/31/2024	145,420	14,708	N/A	N/A	N/A
2/29/2024	141,706	13,969	5,152	18,188	N/A
11/30/2023	139,276	14,330	N/A	N/A	N/A
8/31/2023	135,688	13,655	2,186	12,416	N/A
5/31/2023	134,033	14,160	N/A	N/A	N/A
2/28/2023	128,330	11,742	4,819	12,727	N/A
11/30/2022	125,411	12,962	N/A	N/A	N/A
8/31/2022	121,261	11,160	8,832	12,698	N/A
5/31/2022	118,825	8,927	N/A	N/A	N/A
2/28/2022	120,193	9,658	15,006	19,199	N/A
11/30/2021	120,351	9,746	N/A	N/A	N/A
8/31/2021	120,135	10,559	12,153	15,796	N/A
5/31/2021	117,389	11,499	N/A	N/A	N/A
2/28/2021	114,510	9,250	1,901	5,289	N/A
11/30/2020	122,736	8,996	N/A	N/A	N/A
8/31/2020	130,517	14,839	19,468	23,638	N/A
5/31/2020	136,641	16,894	N/A	N/A	N/A
2/29/2020	140,992	18,694	23,669	27,395	N/A
11/30/2019	139,912	21,295	N/A	N/A	N/A
8/31/2019	137,425	17,594	N/A	16,497	N/A
5/31/2019	139,142	17,665	N/A	N/A	N/A
2/28/2019	143,408	19,204	N/A	15,772	N/A
11/30/2018	140,891	16,608	N/A	N/A	N/A
8/31/2018	143,791	18,891	N/A	21,587	N/A
5/31/2018	145,288	18,897	N/A	N/A	N/A
2/28/2018	147,870	19,119	N/A	30,453	N/A
11/30/2017	145,749	17,895	N/A	N/A	N/A
8/31/2017	144,941	20,495	N/A	25,077	N/A
5/31/2017	143,853	19,540	N/A	N/A	N/A
2/28/2017	145,925	20,395	N/A	19,910	N/A
11/30/2016	149,298	20,806	N/A	N/A	N/A
8/31/2016	153,871	17,694	N/A	27,819	N/A
5/31/2016	160,325	18,778	N/A	N/A	N/A
2/29/2016	161,852	17,784	N/A	30,923	N/A
11/30/2015	164,086	19,626	N/A	N/A	N/A
8/31/2015	162,119	18,586	N/A	25,757	N/A
5/31/2015	158,667	18,321	N/A	N/A	N/A

애널리스트 향후 성장 전망

수입 대 저축률: 4530 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -1.7%).

수익 vs 시장: 4530 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -1.7%).

고성장 수익: 4530 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: 4530 의 수익(연간 4%)이 JP 시장(연간 6.5%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: 4530 의 수익(연간 4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: 4530의 자본 수익률은 3년 후 4.9%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/14 14:37
종가	2026/05/08 00:00
수익	2026/02/28
연간 수익	2026/02/28

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Hisamitsu Pharmaceutical Co., Inc.는 9명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Ritsuo Watanabe	BofA Global Research
Hidemaru Yamaguchi	Citigroup Inc
Akitada Iwasa	Daiwa Securities Co. Ltd.

This company listing is no longer active

Hisamitsu Pharmaceutical 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Price target decreased by 10% to JP¥4,350

Consensus EPS estimates increase by 23%

Price target increased by 7.8% to JP¥4,850

Consensus EPS estimates increase by 12%

Price target increased by 8.0% to JP¥4,700

Price target decreased by 15% to JP¥4,250

Recent updates

Hisamitsu Pharmaceutical Co., Inc.(TSE:4530) dropped from FTSE All-World Index (USD)

Full year 2026 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 28, 2026

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2026 Results on Apr 13, 2026

New major risk - Revenue and earnings growth

Taiyo Kosan Co., Ltd. completed the acquisition of additional 59.38% stake in Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) from Takasago International Corporation (TSE:4914), Yomeishu Seizo Co.,Ltd. (TSE:2540), The Bank of Saga Ltd. (TSE:8395) and others for approximately ¥250 billion.

Third quarter 2026 earnings released: EPS: JP¥69.15 (vs JP¥62.32 in 3Q 2025)

Hisamitsu Pharmaceutical Co., Inc. Revises Dividend Guidance for the Fiscal Year Ending February 28, 2026

New minor risk - Share price stability

Taiyo Kosan Co., Ltd. agreed to acquire a %97.49 stake in Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) in a management buyout transaction for approximately ¥380.6 billion.

What Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) 25% Share Price Gain Is Not Telling You

Investor sentiment improves as stock rises 18%

These 4 Measures Indicate That Hisamitsu Pharmaceutical (TSE:4530) Is Using Debt Safely

Does Hisamitsu Pharmaceutical (TSE:4530) Deserve A Spot On Your Watchlist?

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥60.00

First half dividend of JP¥60.00 announced

Hisamitsu Pharmaceutical's (TSE:4530) Earnings Are Of Questionable Quality

Second quarter 2026 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of JP¥60.00 per share

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Price target decreased by 10% to JP¥4,350

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 3,000,000 shares, representing 4.09% for ¥15,000 million.

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Final dividend increased to JP¥60.00

Consensus EPS estimates increase by 23%

Price target increased by 7.8% to JP¥4,850

We Think That There Are Issues Underlying Hisamitsu Pharmaceutical's (TSE:4530) Earnings

Hisamitsu Pharmaceutical Co., Inc. Announces Exiting of Sugiyama, Kosuke as Director

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 22, 2025

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2026 Results on Oct 09, 2025

With EPS Growth And More, Hisamitsu Pharmaceutical (TSE:4530) Makes An Interesting Case

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2025 Results on Apr 10, 2025

Upcoming dividend of JP¥45.00 per share

Does Hisamitsu Pharmaceutical (TSE:4530) Have A Healthy Balance Sheet?

Consensus EPS estimates increase by 12%

Price target increased by 8.0% to JP¥4,700

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be ¥45.00

Third quarter 2025 earnings released: EPS: JP¥62.32 (vs JP¥48.25 in 3Q 2024)

Hisamitsu Pharmaceutical Co., Inc. Announces Commemorative Dividend for the Fiscal Year Ending February 28, 2025

Hisamitsu Pharmaceutical (TSE:4530) Is Due To Pay A Dividend Of ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2025 Results on Jan 09, 2025

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

First half dividend of JP¥45.00 announced

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

Upcoming dividend of JP¥45.00 per share

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2025 Results on Oct 10, 2024

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. Provides Commemorative Dividend for the Fiscal Year Ending February 28, 2025

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Final dividend of JP¥45.00 announced

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2025 Results on Jul 11, 2024

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,400,000 shares, representing 3.17% for ¥8,901.6 million.

Full year 2024 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2024 Results on Apr 11, 2024